References
- Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Current management of mantle cell lymphoma. Drugs 2007; 67: 1689–1702
- Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma – results of a Prospective Randomized Trial of the European MCL Network. Blood 2005; 105: 2677–2684
- Romaguera J E, Fayad L, Rodriguez M A, Broglio K R, Hagemeister F B, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023
- Till B G, Gooley T A, Crawford N, Gopal Ak, Maloney D G, Petersdorf S H, et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma, in press
- Ritchie D S, Seymour J F, Grigg A P, Roberts A W, Hoyt R, Thompson S, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007; 86: 101–105
- Vose J, Loberiza F, Bierman P, Bociek G, Armitage J. Mantle cell lymphoma (MCL): induction therapy with HyperCVAD/high-dose methotrexate and cytarabine (M-C) (+/− rituximab) improves results of autologous stem cell transplant in first remission. J Clin Oncol 2006; 18S: 424s
- Epner E M, Unger J, Miller T, Rimza L, Spier C, Leblanc M, et al. A multi center trial of hyperCVAD + RITUXAN in patients with newly diagnosed mantle cell lymphoma. Blood 2007; 110: 388
- Martin P, Chadburn A, Christos P, Furmann R, Ruan J, Joyce M A, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: Overall survival exceeding seven years with conservative therapies. Ann Oncol 2008, in press
- Dreyling M, Hoster E, Hermine O, Kluin-Nelemans J C, Walewski J, Trneny M, et al. European MCL network: an update on current first line trials. Blood 2007; 110: 388